Today, PamGene International B.V., an in-vitro diagnostics company focused on the development and commercialization of blood-based immunotherapy selection tests, highlightseight publications in international journals that have confirmed that kinase-activity profiling can aid disease understanding and treatment development. These papers follow a late-2020 article in the Journal for ImmunoTherapy of Cancer on predicting immunotherapy response using the IOpener®, PamGene’s blood-based diagnostic test, with the company’s kinome activity profiling technology at its basis.